Acquisition History / Roche / 89bio, Inc.
Roche Acquires 89bio, Inc.
Announced September 18, 2025 — $3.50B
What happened
89bio agreed on September 18, 2025 to be acquired by Roche for $14.50 per share in cash at closing plus a non-tradeable contingent value right worth up to $6.00 per share on milestones, for a total transaction equity value of up to approximately $3.5B on a fully diluted basis.
- Acquirer
- Roche
- Target
- 89bio, Inc.
- Announced
- September 18, 2025
- Price
- $3.50B
- Industry
- Liver and cardiometabolic biotechnology
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Roche acquire 89bio, Inc.?
Roche acquired 89bio, Inc. on September 18, 2025. This was Roche's 1st publicly tracked acquisition out of 1 we have on record.
How much did Roche pay for 89bio, Inc.?
Roche paid $3.50B for 89bio, Inc..
What does 89bio, Inc. do?
89bio agreed on September 18, 2025 to be acquired by Roche for $14.50 per share in cash at closing plus a non-tradeable contingent value right worth up to $6.00 per share on milestones, for a total transaction equity value of up to approximately $3.5B on a fully diluted basis.
What other Liver and cardiometabolic biotechnology companies has Roche acquired?
89bio, Inc. is Roche's only publicly tracked acquisition in Liver and cardiometabolic biotechnology so far.